Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
Posted: 23 May 2023 Immutep Limited a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that efti, a soluble LAG-3 protein and first-in-class MHC Class II agonist, in combination with MSD’s (Merck & Co.,…
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer
Posted: 23 May 2023 Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received positive feedback from the US Food and Drug Administration (FDA), regarding the Company’s late-stage…
Artificial Intelligence powers second-skin-like wearable tech
Posted: 23 May 2023 A new ultra-thin skinpatch with nanotechnology able to monitor 11 human health signals has been developed by researchers at Monash University. Researchers from the Faculty of Engineering and Faculty of Information Technology combined nanotechnology…
New Centre for Advanced Defence Research and Enterprise established
Posted: 23 May 2023 A Centre for Advanced Defence Research and Enterprise (CADRE-OCE) to develop new concepts and technologies to protect Defence personnel, first responders and the general community has been launched at the University of Melbourne. The…
Amplia receives grant to collaborate with CSIRO
Posted: 23 May 2023 Amplia Therapeutics Limited, is pleased to announce it has received grant funding to undertake a research collaboration with Australia’s national science agency CSIRO to develop novel topical formulations of the Company’s FAK inhibitors. Amplia…
Clue to age-related muscle wasting may lie in killifish
Posted: 23 May 2023 As we age, our muscles start to waste. Called sarcopenia, it happens to us all if we live long enough, but no one has ever understood why it happens. Now new research from the Australian…
Optiscan oral study published in prestigious medical journal
Posted: 23 May 2023 Optiscan Imaging Limited (ASX: OIL) is pleased to announce the publication of readout results of its oral cancer imaging study conducted by Dr. Camile Farah and his team at the Australian Centre for Oral…
Funding boost advances research on cancer vaccine
Posted: 16 May 2023 New research that could lead to a vaccine for patients with hard-to-treat cancers has been backed with over $900,000 in funding from the Medical Research Future Fund (MRFF). The WEHI-led project aims to enhance…
Advanced immunotherapy may hold promise for children with brain cancer
Posted: 16 May 2023 An advanced immunotherapy treatment could hold promise for children with an inoperable type of brain cancer, according to new research. At a glance Diffuse Intrinsic Pontine Glioma (DIPG) is an aggressive type of brain…
Innovative Peter Mac Trial to Improve Patient Recovery from Surgery
Posted: 16 May 2023 A ground-breaking trial using pharmacogenomics to improve patient recovery following surgery is now underway at Peter Mac in collaboration with the University of Adelaide, Monash University, and the University of Melbourne. The research –…
Funding boost advances research on cancer vaccine
Posted: 12 May 2023 New research that could lead to a vaccine for patients with hard-to-treat cancers has been backed with over $900,000 in funding from the Medical Research Future Fund (MRFF). The WEHI-led project aims to enhance…
Victorian Government to accelerate Bionics Institute’s new hearing test for babies, EarGenie, to commercialisation.
Posted: 12 May 2023 Bionic Institute’s novel hearing diagnostic system, EarGenie®, moves closer to commercialisation with a new government grant of over $1m The Bionics Institute’s new hearing diagnostic system for babies, EarGenie, is one step closer to…
